Difference between Role of Nebulized Salbutamol and Nebulized Normal Saline in Treatment of Transient Tachypnea of New Born

Background: Transient Tachypnea of the Newborn (TTN) is a common respiratory condition in neonates, characterized by rapid breathing due to delayed lung fluid clearance. Nebulized Salbutamol, a beta-agonist, is a potential treatment for improving respiratory outcomes. Objective: To compare the mean respiratory rate with inhaled salbutamol and normal saline in transient tachypnea of new born. Study Design: Randomized controlled trial. Duration and Place of Study: The study was conducted at the Department of Pediatrics, POF Hospital Wah Cantt, from June 2023 to December 2023. Methodology: A total of 60 neonates with TTN were randomly assigned to two groups: Group A (Salbutamol) and Group B (Normal Saline). Patients were assessed for respiratory rate before treatment and at intervals of 30 minutes, 60 minutes, and 4 hours after nebulization. The main outcome measure was the change in respiratory rate at 4 hours’ post-treatment. Results: At baseline, the respiratory rates were similar in both groups: 77.00 ± 2.03 BPM in Group A and 76.90 ± 1.84 BPM in Group B (p = 0.843). At 30 minutes post-treatment, respiratory rates remained similar: Group A (72.17 ± 1.68 BPM) vs. Group B (72.37 ± 1.51 BPM, p = 0.631). At 60 minutes, no significant difference was observed: Group A (69.80 ± 1.76 BPM) vs. Group B (70.10 ± 1.70 BPM, p = 0.507). However, at 4 hours, Group A showed a significant improvement with a respiratory rate of 60.83 ± 1.62 BPM, while Group B had 76.27 ± 1.08 BPM (p < 0.001). Conclusion: Our study has demonstrated that nebulized Salbutamol is an effective treatment for reducing respiratory rates in neonates with TTN, with significant improvement observed at 4 hours post-treatment compared to normal saline.